Form 4: Longboard Pharmaceuticals CEO Exercises Stock Options and Gifts Shares

Longboard Pharmaceuticals CEO, Kevin Robert Lind, exercised stock options and gifted shares to a donor-advised trust on November 13, 2024.

Summary

• On November 13, 2024, Kevin Robert Lind, CEO of Longboard Pharmaceuticals, exercised 12,808 stock options at a price of $3.1232 per share.
• He also gifted 80,000 shares of common stock to a donor-advised trust.
• Following these transactions, Mr. Lind directly owns 363,740 shares of common stock and 255,377 stock options.
• The stock options were granted previously and vested in 24 equal monthly installments starting November 27, 2022.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing insider transactions, which is neither positive nor negative for the company's overall outlook.

Positives

• The exercise of stock options by the CEO indicates confidence in the company's future prospects.
• The gifting of shares to a donor-advised trust may have positive tax implications for the CEO.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders when they make transactions involving their company's securities. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Stock option exercises and share gifting are common practices among executives in publicly traded companies.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement.
• The vesting schedule of the stock options is typical for executive compensation packages.

Stakeholder Impact

• The transactions may have a minor impact on the company's share price, but are not expected to be significant.
• The gifting of shares to a donor-advised trust does not directly impact other stakeholders.

Key Dates

Keywords

stock options, insider trading, share gifting, beneficial ownership, Longboard Pharmaceuticals, LBPH, CEO, Kevin Robert Lind